Scleroderma Foundation's 13th Annual National Patient Education Conference Is Here PDF Print E-mail
Wednesday, 06 July 2011 10:31
Nearly 600 people are anticipated to visit the heart of San Francisco Friday, July 8, through Sunday, July 10, for the Scleroderma Foundation's 13th Annual National Patient Education Conference. Patients, family members, caregivers, doctors and other health care professionals representing 40 states, the District of Columbia, Canada and Mexico will converge at the Hilton San Francisco Union Square for this engaging and educational event that focuses on scleroderma, a rare autoimmune disease.

This year's conference features a variety of workshops hosted by leading scleroderma researchers and medical professionals. Andreas Baxevanis, Ph.D., will give the opening keynote address on the promise of genomics and genome-based personal health care in disease management. James Lemons, Ed.D., will present the closing keynote on "Pain – The Psychology and Physiology: There is Hope." Dr. Baxevanis is Assistant Director for Computational Bioscience, Office of Intramural Research at the National Institutes of Health (NIH), and Associate Investigator, Division of Intramural Research at the National Human Genome Research Institute in Bethesda, Md. Dr. Lemons is the director of The Lemons Center for Behavioral Pain Management in Lenexa, Kan., and a medical psychologist.

Other conference highlights include:
  • Fifty-six workshops and panel discussions for patients, family members and caregivers.
  • Special sessions for children with scleroderma and their families.
  • Representatives from the University of Texas Scleroderma Family Registry and DNA Repository and the University of Texas Southwestern Morphea Registry and DNA Repository will be at the conference seeking interested individuals to serve as donors and controls for scleroderma research.
  • Annual Awards Banquet to honor Scleroderma Foundation members, volunteers and chapters of the Foundation for their dedication and work to advance the mission of the Scleroderma Foundation, and bring awareness to the issues facing the scleroderma patient community.

For more information about scleroderma and the National Patient Education Conference, visit www.scleroderma.org.

 
More articles :

» Stem Cell Transplant Helps Retired New Jersey Principal

Covered within a recent article, New Jersey resident, Michael George feels “reborn” after having his own implanted in him to treat his in a new . The retired William C. McGinnis School principal, who in April was taken off all medications,...

» Lupus, A Widespread and Chronic Autoimmune Disease

Lupus is a widespread and chronic disease that, for unknown reasons, causes the immune system to attack the body’s own tissues and organs, including the joints, kidneys, heart, lungs, brain and skin. Lupus, an important disease for...

» Platelet Gel In The Treatment Of Severe Scleroderma Skin Ulcers

Dilia Giuggioli, Michele Colaci, Andreina Manfredi, Mariateresa Mariano and Clodoveo FerriSystemic sclerosis (SSc) is characterized by microvascular damage and fibrosis of the skin and internal organs. Non-healing skin ulcers, mainly non-venous leg...

» New Hope for Patients

Pulmonary Fibrosis (PF) and (PAH) are incurable rare lung diseases and are the leading cause of mortality in patients with Systemic Sclerosis (SSc). However patients might have a reason to breathe easier since researchers from the University of...

» Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma

Alexander Kreuter, MD; Thilo Gambichler, MD; Frank Breuckmann, MD; Sebastian Rotterdam, MD; Marcus Freitag, MD; Markus Stuecker, MD; Klaus Hoffmann, MD; Peter Altmeyer, MDArch Dermatol. 2005;141:847-852Objective: To evaluate the efficacy of pulsed...

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...